Group 1 - The core point of the article is that Jiyuan Holdings Group Co., Ltd. (*ST Jiyuan) will be delisted from the Shenzhen Stock Exchange on May 29, 2025, due to triggering mandatory delisting rules after its stock price remained below 1 yuan for 20 consecutive trading days [1][3] - The company has experienced continuous losses since 2019, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023 [3] - Jiyuan Holdings has faced significant goodwill impairment risks, totaling over 1.5 billion yuan from 2019 to 2024, which has directly contributed to its net profit losses [3] Group 2 - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd. and transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical [3] - Since its rebranding in 2017, the company has aggressively pursued mergers and acquisitions, acquiring over ten companies within three years, leading to a dual business model of "chemicals + pharmaceuticals" [3] - In 2024, the company's revenue declined by 3.69%, and its losses expanded to 439 million yuan [3] Group 3 - As of 2025, a total of 11 companies have been delisted from the A-share market, with *ST Jiyuan being one of them, alongside others like *ST Meixun and *ST Bo Xin [4] - The reasons for delisting include breaches of face value, market value, voluntary delisting applications, and forced delisting due to major violations [4]

Core Viewpoint - Jiyuan Holdings Group Co., Ltd. has been announced to be delisted from the Shenzhen Stock Exchange due to its stock price falling below 1 yuan for twenty consecutive trading days, with the delisting effective on May 29, 2025 [1] Group 1: Company Performance and Financials - Jiyuan Holdings, originally a chemical company, transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, establishing a dual business model of "chemicals + pharmaceuticals" [3] - The company engaged in aggressive acquisitions, acquiring over ten companies within three years, with its pharmaceutical segment accounting for 70% of total revenue at its peak, leading to a market capitalization exceeding 5 billion yuan [3] - However, the acquired companies' performance deteriorated post-acquisition, with Zhejiang Yalida Gelatin Co., Ltd. reporting a 94% drop in net profit in 2019, and Changchun Puhua Pharmaceutical Co., Ltd. incurring direct losses [3] - Since 2019, Jiyuan Holdings has been in a continuous loss state, accumulating losses exceeding 3.7 billion yuan [4] Group 2: Attempts at Restructuring and Ownership Changes - The company has made several attempts to change ownership in response to its financial struggles, but all efforts have failed [5] - In 2019, an agreement to transfer shares to Jilin Jisheng Asset Management was terminated due to disagreements on key terms [5] - A proposed acquisition of Xiu Zheng Pharmaceutical was also abandoned due to regulatory uncertainties, leading to scrutiny from the Shenzhen Stock Exchange [5][6] - In 2020, a deal to transfer control to Ben Cao Hui Pharmaceutical faced disputes over payment, resulting in legal proceedings [6]

Investment Rating - The report maintains a "Buy" rating for Qingdao Beer [3][6] Core Views - The company is focusing on cross-industry expansion and is expected to leverage the peak season for growth. The core product strategy revolves around the "1+1+1+2+N" combination development, with an emphasis on strengthening classic products and achieving higher growth in high-end and ultra-high-end series [1][2] - The acquisition of 100% equity in Jimo Huangjiu for 665 million yuan is a significant step in diversifying the beverage portfolio, allowing for seasonal sales balance between Huangjiu and beer, and enhancing supply chain and sales channel efficiency [2] - The company anticipates better performance in terms of volume and price during the peak season, driven by improved weather conditions, stable demand, and supportive domestic policies. The cost structure is expected to improve, contributing to profit elasticity [2] Financial Summary - The projected net profit for the company is expected to reach 4.81 billion yuan in 2025, with a year-on-year growth of 10.7%. The corresponding P/E ratios for 2025, 2026, and 2027 are 21x, 19x, and 18x respectively [3][5] - Revenue is projected to decline to 32.14 billion yuan in 2024, followed by a recovery to 33.73 billion yuan in 2025, reflecting a growth rate of 5% [5] - The company’s net profit margin is expected to improve from 12.6% in 2023 to 15.7% by 2027, indicating a positive trend in profitability [10]